Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical alicaforsen enema in antibiotic-refractory primary idiopathic pouchitis
2013-002952-34Phase 3Completed
- Sponsor
- Atlantic Pharmaceuticals
- Start
- Oct 2015
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pouchitis comparing alicaforsen enema with placebo enema (2 arms). Primary endpoints: Endoscopic healing of pouchitis and Improvement in clinical symptoms of pouchitis. Started Oct 2015; status: completed.
02
Drugs
alicaforsen
03
Conditions
pouchitis
Beyond the preview
Go deeper on 2013-002952-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002952-34.